The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Spirin N.N.

Yaroslavl State Medical University

Kiselev D.V.

Yaroslavl State Medical University

Karpova M.S.

Yaroslavl State Medical University

Neuropathic pain syndromes in patients with multiple sclerosis

Authors:

Spirin N.N., Kiselev D.V., Karpova M.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7‑2): 22‑30

DOI: 10.17116/jnevro202112107222

Views: 6259

Downloaded: 173

Download PDF (RU)
Contact the author
Table of contents

NEUROPATHIC PAIN SYNDROMES IN PATIENTS WITH MULTIPLE SCLEROSIS
NEUROPATHIC PAIN SYNDROMES IN PATIENTS WITH MULTIPLE SCLEROSIS

To cite this article:

Spirin NN, Kiselev DV, Karpova MS. Neuropathic pain syndromes in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7‑2):22‑30. (In Russ.)
https://doi.org/10.17116/jnevro202112107222

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Close metadata
Recommended articles:
The inte­nsity of neuropathic pain and the seve­rity of inso­mnia in diabetic poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):87-92
Biobanking in clinical trials invo­lving multiple scle­rosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):7-15
Opti­cal cohe­rence tomo­graphy angiography in the diagnosis of multiple scle­rosis. Russian Annals of Ophthalmology. 2024;(2):63-70
Features of course of pain syndrome in patients with schwannomatosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):48-52
A role of cere­brovascular diseases in the progression of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):53-57
Como­rbid diso­rders and risk factors for neiropathic pain in distal diabetic poly­neuropathy. Russian Journal of Pain. 2024;(2):41-48
Opti­cal cohe­rence tomo­graphy in the diagnosis of multiple scle­rosis. Russian Annals of Ophthalmology. 2024;(3):59-68
Questionnaires for arm function asse­ssment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):36-42
Features of primary forms of headache in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):70-73
Neurofilament light chain: a diagnostic pote­ntial for multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):115-119

Among the numerous pain syndromes (PS) of various localizations and types, observed in patients with multiple sclerosis (MS), the greatest attention of researchers is attracted by neuropathic PS. Neuropathic PS are often present already in the early stage of MS, significantly reduce the quality of life, hinder the social adaptation of patients, poorly respond to therapy. Central neuropathic PS, which pathogenesis is closely related with plaques in the central nervous system, are most common in patients with MS. Diagnostics of neuropathic PS in MS is based mainly on typical clinical symptoms; MRI and neurophysiological methods data are of secondary importance. This review focuses on modern concepts of three main neuropathic PS in MS: ongoing extremity pain, trigeminal neuralgia and Lhermitte’s sign. Clinical symptoms of neuropathic PS, current ideas about their pathogenetic mechanisms, MRI and neurophysiological techniques data and the existing approaches to conservative therapy and surgical treatment based on randomized trials data are presented.

Keywords:

multiple sclerosis
neuropathic pain
ongoing extremity pain
trigeminal neuralgia
Lhermitte’s sign

Authors:

Spirin N.N.

Yaroslavl State Medical University

Kiselev D.V.

Yaroslavl State Medical University

Karpova M.S.

Yaroslavl State Medical University

Received:

20.05.2021

Accepted:

21.05.2021

List of references:

  1. Chisari CG, Sgarlata E, Arena S. et al. An update on the pharmacological management of pain in patients with multiple sclerosis. Expert Opin Pharmacother. 2020;21(18):2249-2263. https://doi.org/10.1080/14656566.2020.1757649
  2. Brochet B, Deloire MS, Ouallet JC. et al. Pain and quality of life in the early stages after multiple sclerosis diagnosis: a 2-year longitudinal study. Clin J Pain. 2009;25(3):211-217.  https://doi.org/10.1097/AJP.0b013e3181891347
  3. Pöllmann W, Feneberg W, Erasmus LP. Schmerzen bei Multipler Sklerose-ein immer noch unterschätztes Problem. Einjahresprävalenz von Schmerzsyndromen, ihr Stellenwert und die Versorgungsqualität bei stationär behandelten MS-Patienten. Nervenarzt. 2004;75(2):135-140.  https://doi.org/10.1007/s00115-003-1656-5
  4. Truini A, Barbanti P, Pozzilli C, Cruccu G. A mechanism-based classification of pain in multiple sclerosis. J Neurol. 2013;260(2):351-367.  https://doi.org/10.1007/s00415-012-6579-2
  5. Khan N, Smith MT. Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models. Inflammopharmacology. 2014;22(1):1-22.  https://doi.org/10.1007/s10787-013-0195-3
  6. Jensen TS, Baron R, Haanpää M. et al. A new definition of neuropathic pain. Pain. 2011;152(10):2204-2205. https://doi.org/10.1016/j.pain.2011.06.017
  7. Davydov OS, Yakhno NN, Kukushkin ML, et al. Neuropathic pain: clinical guidelines on the diagnostics and treatment from the Russian Association for the Studying of Pain. Rossijskij Zhurnal Boli. 2018;16(57):5-41. (In Russ.). https://doi.org/10.25731/RASP.2018.04.025
  8. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis--prevalence and clinical characteristics. Eur J Pain. 2005;9(5):531-542.  https://doi.org/10.1016/j.ejpain.2004.11.005
  9. Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. Neurology. 1988;38(12):1830-1834. https://doi.org/10.1212/wnl.38.12.1830
  10. Solaro C, Trabucco E, Messmer Uccelli M. Pain and multiple sclerosis: pathophysiology and treatment. Curr Neurol Neurosci Rep. 2013;13(1):320.  https://doi.org/10.1007/s11910-012-0320-5
  11. Feketová S, Waczulíková I, Valkovič P, et al. Central Pain in Patients with Multiple sclerosis. J Mult Scler (Foster City). 2017;4:208-214.  https://doi.org/10.4172/2376-0389.1000208
  12. Watson JC, Sandroni P. Central Neuropathic Pain Syndromes. Mayo Clin Proc. 2016;91(3):372-385.  https://doi.org/10.1016/j.mayocp.2016.01.017
  13. Boivie J. Central pain. Wall and Melzack´s Textbook of pain. Elsevier Inc., London. 2006;1057-1075.
  14. Gormsen L, Rosenberg R, Bach FW, Jensen TS. Depression, anxiety, health-related quality of life and pain in patients with chronic fibromyalgia and neuropathic pain. Eur J Pain. 2010;14(2):127.e1-8.  https://doi.org/10.1016/j.ejpain.2009.03.010
  15. Ferini-Strambi L. Neuropathic Pain and Sleep: A Review. Pain Ther. 2017;6(suppl 1):19-23.  https://doi.org/10.1007/s40122-017-0089-y
  16. Svendsen KB, Jensen TS, Overvad K, et al. Pain in patients with multiple sclerosis: a population-based study. Arch Neurol. 2003;60(8):1089-1094. https://doi.org/10.1001/archneur.60.8.1089
  17. Nurmikko TJ, Gupta S, Maclver K. Multiple sclerosis-related central pain disorders. Curr Pain Headache Rep. 2010;14(3):189-195.  https://doi.org/10.1007/s11916-010-0108-8
  18. O’Connor AB, Schwid SR, Herrmann DN, et al. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain. 2008;137(1):96-111.  https://doi.org/10.1016/j.pain.2007.08.024
  19. Martinelli BF, Colombo B, Annovazzi P, et al. Lifetime and actual prevalence of pain and headache in multiple sclerosis. Mult Scler. 2008;14(4):514-521.  https://doi.org/10.1177/1352458507085551
  20. Danilov AB, Davydov OS. Nejropaticheskaya bol’. M.: Borges; 2007. (In Russ.).
  21. Osterberg A, Boivie J. Central pain in multiple sclerosis — sensory abnormalities. Eur J Pain. 2010;14(1):104-110.  https://doi.org/10.1016/j.ejpain.2009.03.003
  22. Moisset X, Ouchchane L, Guy N, et al. Migraine headaches and pain with neuropathic characteristics: comorbid conditions in patients with multiple sclerosis. Pain. 2013;154(12):2691-2699. https://doi.org/10.1016/j.pain.2013.07.050
  23. Svendsen KB, Jensen TS, Hansen HJ, Bach FW. Sensory function and quality of life in patients with multiple sclerosis and pain. Pain. 2005;114(3):473-481.  https://doi.org/10.1016/j.pain.2005.01.015
  24. Bouhassira D, Lantéri-Minet M, Attal N, et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136(3):380-387.  https://doi.org/10.1016/j.pain.2007.08.013
  25. Leijon G, Boivie J. Central post-stroke pain — the effect of high and low frequency TENS. Pain. 1989;38(2):187-191.  https://doi.org/10.1016/0304-3959(89)90237-6
  26. Periquet MI, Novak V, Collins MP, et al. Painful sensory neuropathy: prospective evaluation using skin biopsy. Neurology. 1999;53(8):1641-1647. https://doi.org/10.1212/wnl.53.8.1641
  27. Morales Y, Parisi JE, Lucchinetti CF. The pathology of multiple sclerosis: evidence for heterogeneity. Adv Neurol. 2006;98:27-45. PMID: 16400825.
  28. Gormsen L, Rosenberg R, Bach FW, Jensen TS. Depression, anxiety, health-related quality of life and pain in patients with chronic fibromyalgia and neuropathic pain. Eur J Pain. 2010;14(2):127.e1-8.  https://doi.org/10.1016/j.ejpain.2009.03.010
  29. Ferini-Strambi L. Neuropathic Pain and Sleep: A Review. Pain Ther. 2017;6(suppl 1):19-23.  https://doi.org/10.1007/s40122-017-0089-y
  30. Churyukanov MV, Alekseyev VV, Kukushkin ML, Yakhno NN. Psychological features of patients with central pain syndrome in multiple sclerosis. Nevrologija, Nejropsihiatrija, Psihosomatika. 2011;3(2):42-46. (In Russ.). https://doi.org/10.14412/2074-2711-2011-145
  31. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329(7460):253.  https://doi.org/10.1136/bmj.38149.566979
  32. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819.  https://doi.org/10.1212/01.wnl.0000176753.45410.8b
  33. Rossi S, Mataluni G, Codecà C, et al. Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. Eur J Neurol. 2009;16(3):360-366.  https://doi.org/10.1111/j.1468-1331.2008.02496.x
  34. Attal N, Cruccu G, Baron R. et al. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.  https://doi.org/10.1111/j.1468-1331.2010.02999.x
  35. Henze T, Rieckmann P, Toyka KV; Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006;56(2):78-105.  https://doi.org/10.1159/000095699
  36. Di Stefano G, De Stefano G, Di Lionardo A, et al. Pharmacotherapeutic Options for Managing Pain in Multiple Sclerosis. CNS Drugs. 2020;34(7):749-761.  https://doi.org/10.1007/s40263-020-00731-7
  37. Chisari CG, Sgarlata E, Arena S, et al. An update on the pharmacological management of pain in patients with multiple sclerosis. Expert Opin Pharmacother. 2020;21(18):2249-2263. https://doi.org/10.1080/14656566.2020.1757649
  38. Hooge JP, Redekop WK. Trigeminal neuralgia in multiple sclerosis. Neurology. 1995;45(7):1294-1296. https://doi.org/10.1212/wnl.45.7.1294
  39. Solaro C, Brichetto G, Amato MP, et al.; PaIMS Study Group. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology. 2004;63(5):919-921.  https://doi.org/10.1212/01.wnl.0000137047.85868.d6
  40. Solaro C, Cella M, Signori A, et al.; Neuropathic Pain Special Interest Group of the Italian Neurological Society. Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. J Neurol. 2018;265(4):828-835.  https://doi.org/10.1007/s00415-018-8758-2
  41. Solaro C, Brichetto G, Amato MP, et al.; PaIMS Study Group. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology. 2004;63(5):919-921.  https://doi.org/10.1212/01.wnl.0000137047.85868.d6
  42. Cruccu G, Finnerup NB, Jensen TS, et al. Trigeminal neuralgia: New classification and diagnostic grading for practice and research. Neurology. 2016;87(2):220-228.  https://doi.org/10.1212/WNL.0000000000002840
  43. Di Stefano G, Maarbjerg S, Truini A. Trigeminal neuralgia secondary to multiple sclerosis: from the clinical picture to the treatment options. J Headache Pain. 2019;20(1):20.  https://doi.org/10.1186/s10194-019-0969-0
  44. Cruccu G, Biasiotta A, Di Rezze S, et al. Trigeminal neuralgia and pain related to multiple sclerosis. Pain. 2009;143(3):186-191.  https://doi.org/10.1016/j.pain.2008.12.026
  45. Truini A, Prosperini L, Calistri V, et al. A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis. Neurology. 2016;86(22):2094-2099. https://doi.org/10.1212/WNL.0000000000002720
  46. Maarbjerg S, Gozalov A, Olesen J, Bendtsen L. Trigeminal neuralgia — a prospective systematic study of clinical characteristics in 158 patients. Headache. 2014;54(10):1574-1582. https://doi.org/10.1111/head.12441
  47. Zakrzewska JM. Multi-dimensionality of chronic pain of the oral cavity and face. J Headache Pain. 2013;14(1):37.  https://doi.org/10.1186/1129-2377-14-37
  48. Di Stefano G, Maarbjerg S, Nurmikko T, et al. Triggering trigeminal neuralgia. Cephalalgia. 2018;38(6):1049-1056. https://doi.org/10.1177/0333102417721677
  49. Cruccu G, Gronseth G, Alksne J, et al. American Academy of Neurology Society; European Federation of Neurological Society. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15(10):1013-1028. https://doi.org/10.11115
  50. Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogenesis. Brain. 2001;124(Pt 12):2347-2360. https://doi.org/10.1093/brain/124.12.2347
  51. Antonini G, Di Pasquale A, Cruccu G, et al. Magnetic resonance imaging contribution for diagnosing symptomatic neurovascular contact in classical trigeminal neuralgia: a blinded case-control study and meta-analysis. Pain. 2014;155(8):1464-1471. https://doi.org/10.1016/j.pain.2014.04.020
  52. Broggi G, Ferroli P, Franzini A, et al. Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;68(1):59-64.  https://doi.org/10.1136/jnnp.68.1.59
  53. Burchiel KJ. Abnormal impulse generation in focally demyelinated trigeminal roots. J Neurosurg. 1980;53(5):674-683.  https://doi.org/10.3171/jns.1980.53.5.0674
  54. Devor M, Govrin-Lippmann R, Rappaport ZH. Mechanism of trigeminal neuralgia: an ultrastructural analysis of trigeminal root specimens obtained during microvascular decompression surgery. J Neurosurg. 2002;96(3):532-543.  https://doi.org/10.3171/jns.2002.96.3.0532
  55. Truini A, Garcia-Larrea L, Cruccu G. Reappraising neuropathic pain in humans — how symptoms help disclose mechanisms. Nat Rev Neurol. 2013;9(10):572-582.  https://doi.org/10.1038/nrneurol.2013.180
  56. Obermann M, Yoon MS, Ese D, et al. Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia. Neurology. 2007;69(9):835-841.  https://doi.org/10.1212/01.wnl.0000269670.30045.6b
  57. Cruccu G, Deuschl G. The clinical use of brainstem reflexes and hand-muscle reflexes. Clin Neurophysiol. 2000;111(3):371-387.  https://doi.org/10.1016/s1388-2457(99)00291-6
  58. Cruccu G, Biasiotta A, Galeotti F, et al. Diagnostic accuracy of trigeminal reflex testing in trigeminal neuralgia. Neurology. 2006;66(1):139-141.  https://doi.org/10.1212/01.wnl.0000191388.64530.8f
  59. Swinnen C, Lunskens S, Deryck O, et al. MRI characteristics of trigeminal nerve involvement in patients with multiple sclerosis. Mult Scler Relat Disord. 2013;2(3):200-203.  https://doi.org/10.1016/j.msard.2012.12.002
  60. Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbazepine (tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry. 1966;29(3):265-267.  https://doi.org/10.1136/jnnp.29.3.265
  61. Rockliff BW, Davis EH. Controlled sequential trials of carbamazepine in trigeminal neuralgia. Arch Neurol. 1966;15(2):129-136.  https://doi.org/10.1001/archneur.1966.00470140019003
  62. Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain. 2002;18(1):22-27.  https://doi.org/10.1097/00002508-200201000-00004
  63. Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2005;3:CD001133. Update in: Cochrane Database Syst Rev. 2010;1:CD001133. PMID: 16034857. https://doi.org/10.1002/14651858.CD001133.pub2
  64. Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute and chronic pain in adults. Cochrane Database Syst Rev. 2011;1:CD005451. Update in: Cochrane Database Syst Rev. 2014;4:CD005451. PMID: 21249671; PMCID: PMC4160789. https://doi.org/10.1002/14651858.CD005451.pub2
  65. Di Stefano G, La Cesa S, Truini A, Cruccu G. Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain. J Headache Pain. 2014;15(1):34.  https://doi.org/10.1186/1129-2377-15-34
  66. Ramsaransing G, Zwanikken C, De Keyser J. Worsening of symptoms of multiple sclerosis associated with carbamazepine. BMJ. 2000;320(7242):1113.
  67. Solaro C, Uccelli MM. Management of pain in multiple sclerosis: a pharmacological approach. Nat Rev Neurol. 2011;7(9):519-527.  https://doi.org/10.1038/nrneurol.2011.120
  68. Di Stefano G, Truini A. Pharmacological treatment of trigeminal neuralgia. Expert Rev Neurother. 2017;17(10):1003-1011. https://doi.org/10.1080/14737175.2017.1370375
  69. Solaro C, Boehmker M, Tanganelli P. Pregabalin for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. J Neurol. 2009;256(10):1773-1774. https://doi.org/10.1007/s00415-009-5203-6
  70. Leandri M, Lundardi G, Inglese M, et al. Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. J Neurol. 2000;247(7):556-558.  https://doi.org/10.1007/s004150070157
  71. Solaro CM, Ferriero G. Refactory Trigeminal Neuralgia successfully treated by combination therapy (Pregabalin plus Lamotrigine). Mult Scler Relat Disord. 2018;25:165-166.  https://doi.org/10.1016/j.msard.2018.07.027
  72. D’Aleo G, Sessa E, Di Bella P, et al. Topiramate modulation of R3 nociceptive reflex in multiple sclerosis patients suffering paroxysmal symptoms. J Neurol. 2001;248(11):996-999.  https://doi.org/10.1007/s004150170057
  73. Reder AT, Arnason BG. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995;45(6):1097-1100. https://doi.org/10.1212/wnl.45.6.1097
  74. Pfau G, Brinkers M, Treuheit T, et al. Misoprostol as a therapeutic option for trigeminal neuralgia in patients with multiple sclerosis. Pain Med. 2012;13(10):1377-1378. https://doi.org/10.1111/j.1526-4637.2012.01472.x
  75. DMKG study group. Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol. 2003;250(5):542-545.  https://doi.org/10.1007/s00415-003-1032-1
  76. Pickett GE, Bisnaire D, Ferguson GG. Percutaneous retrogasserian glycerol rhizotomy in the treatment of tic douloureux associated with multiple sclerosis. Neurosurgery. 2005;56(3):537-545; discussion 537-545.  https://doi.org/10.1227/01.neu.0000153907.43563.ff
  77. Mallory GW, Atkinson JL, Stien KJ, et al. Outcomes after percutaneous surgery for patients with multiple sclerosis-related trigeminal neuralgia. Neurosurgery. 2012;71(3):581-586; discussion 586.  https://doi.org/10.1227/NEU.0b013e31825e795b
  78. Krishnan S, Bigder M, Kaufmann AM. Long-term follow-up of multimodality treatment for multiple sclerosis-related trigeminal neuralgia. Acta Neurochir (Wien). 2018;160(1):135-144.  https://doi.org/10.1007/s00701-017-3383-x
  79. Broggi G, Ferroli P, Franzini A, et al. Operative findings and outcomes of microvascular decompression for trigeminal neuralgia in 35 patients affected by multiple sclerosis. Neurosurgery. 2004;55(4):830-838. 
  80. Mohammad-Mohammadi A, Recinos PF, et al. Surgical outcomes of trigeminal neuralgia in patients with multiple sclerosis. Neurosurgery. 2013;73(6):941-950; discussion 950.  https://doi.org/10.1227/NEU.0000000000000128
  81. Zakrzewska JM, Wu J, Brathwaite TS. A Systematic Review of the Management of Trigeminal Neuralgia in Patients with Multiple Sclerosis. World Neurosurg. 2018;111:291-306.  https://doi.org/10.1016/j.wneu.2017.12.147
  82. Berk C, Constantoyannis C, Honey CR. The treatment of trigeminal neuralgia in patients with multiple sclerosis using percutaneous radiofrequency rhizotomy. Can J Neurol Sci. 2003;30(3):220-223.  https://doi.org/10.1017/s0317167100002626
  83. Rogers CL, Shetter AG, Ponce FA, et al. Gamma knife radiosurgery for trigeminal neuralgia associated with multiple sclerosis. J Neurosurg. 2002;97(5 suppl):529-532.  https://doi.org/10.3171/jns.2002.97.supplement
  84. Broggi G, Ferroli P, Franzini A, et al. Role of microvascular decompression in trigeminal neuralgia and multiple sclerosis. Lancet. 1999;354(9193):1878-1879. https://doi.org/10.1016/s0140-6736(99)94422-7
  85. Leandri M. Therapy of trigeminal neuralgia secondary to multiple sclerosis. Expert Rev Neurother. 2003;3(5):661-671.  https://doi.org/10.1586/14737175.3.5.661
  86. Mathieu D, Effendi K, Blanchard J, Séguin M. Comparative study of Gamma Knife surgery and percutaneous retrogasserian glycerol rhizotomy for trigeminal neuralgia in patients with multiple sclerosis. J Neurosurg. 2012;117(suppl):175-180.  https://doi.org/10.3171/2012.6.GKS12987
  87. Dieckmann G, Veras G, Sogabe K. Retrogasserian glycerol injection or percutaneous stimulation in the treatment of typical and atypical trigeminal pain. Neurol Res. 1987;9(1):48-49.  https://doi.org/10.1080/01616412.1987.11739771
  88. Kondziolka D, Lunsford LD, Bissonette DJ. Long-term results after glycerol rhizotomy for multiple sclerosis-related trigeminal neuralgia. Can J Neurol Sci. 1994;21(2):137-140.  https://doi.org/10.1017/s0317167100049076
  89. Kouzounias K, Schechtmann G, Lind G, et al. Factors that influence outcome of percutaneous balloon compression in the treatment of trigeminal neuralgia. Neurosurgery. 2010;67(4):925-934; discussion 934.  https://doi.org/10.1227/NEU.0b013e3181eb5230
  90. Montano N, Papacci F, Cioni B, et al. Percutaneous balloon compression for the treatment of trigeminal neuralgia in patients with multiple sclerosis. Analysis of the potentially prognostic factors. Acta Neurochir (Wien). 2012;154(5):779-783.  https://doi.org/10.1007/s00701-012-1301-9
  91. Bergenheim AT, Asplund P, Linderoth B. Percutaneous retrogasserian balloon compression for trigeminal neuralgia: review of critical technical details and outcomes. World Neurosurg. 2013;79(2):359-368.  https://doi.org/10.1016/j.wneu.2012.03.014
  92. Martin S, Teo M, Suttner N. The effectiveness of percutaneous balloon compression in the treatment of trigeminal neuralgia in patients with multiple sclerosis. J Neurosurg. 2015;123(6):1507-1511. https://doi.org/10.3171/2014.11.JNS14736
  93. Broggi G, Franzini A. Radiofrequency trigeminal rhizotomy in treatment of symptomatic non-neoplastic facial pain. J Neurosurg. 1982;57(4):483-486.  https://doi.org/10.3171/jns.1982.57.4.0483
  94. Kanpolat Y, Berk C, Savas A, Bekar A. Percutaneous controlled radiofrequency rhizotomy in the management of patients with trigeminal neuralgia due to multiple sclerosis. Acta Neurochir (Wien). 2000;142(6):685-689; discussion 689-690.  https://doi.org/10.1007/s007010070113
  95. Tyurnikov VM, Peresedova AV, Gushcha AO, Koval’ KV. Experience in the use of high-frequency selective percutaneous rhizotomy in trigeminal neuralgia associated with multiple sclerosis. Zh Vopr Neirokhir im. N.N. Burdenko. 2015;79(5):34-42.  https://doi.org/10.17116/neiro201579534-42
  96. Montano N, Papacci F, Cioni B, et al. What is the best treatment of drug-resistant trigeminal neuralgia in patients affected by multiple sclerosis? A literature analysis of surgical procedures. Clin Neurol Neurosurg. 2013;115(5):567-572.  https://doi.org/10.1016/j.clineuro.2012.07.011
  97. Cruccu G. Trigeminal Neuralgia. Continuum (Minneap Minn). 2017;23(2, Selected Topics in Outpatient Neurology):396-420.  https://doi.org/10.1212/CON.0000000000000451
  98. Tuleasca C, Carron R, Resseguier N, et al. Multiple sclerosis-related trigeminal neuralgia: a prospective series of 43 patients treated with gamma knife surgery with more than one year of follow-up. Stereotact Funct Neurosurg. 2014;92(4):203-210.  https://doi.org/10.1159/000362173
  99. Przybylowski CJ, Cole TS, Baranoski JF, et al. Radiosurgery for multiple sclerosis-related trigeminal neuralgia: retrospective review of long-term outcomes. J Neurosurg. 2018;56(3):1-8.  https://doi.org/10.3171/2018.5.JNS173194
  100. Alvarez-Pinzon AM, Wolf AL, Swedberg HN, et al. Comparison of Percutaneous Retrogasserian Balloon Compression and Gamma Knife Radiosurgery for the Treatment of Trigeminal Neuralgia in Multiple Sclerosis. World Neurosurg. 2017;97:590-594.  https://doi.org/10.1016/j.wneu.2016.10.028
  101. Holland MT, Teferi N, Noeller J, et al. Stereotactic radio surgery and radio frequency rhizotomy for trigeminal neuralgia in multiple sclerosis: A single institution experience. Clin Neurol Neurosurg. 2017;162:80-84.  https://doi.org/10.1016/j.clineuro.2017.09.004
  102. Ariai MS, Mallory GW, Pollock BE. Outcomes after microvascular decompression for patients with trigeminal neuralgia and suspected multiple sclerosis. World Neurosurg. 2014;81(3-4):599-603.  https://doi.org/10.1016/j.wneu.2013.09.027
  103. Barker FG 2nd, Jannetta PJ, Bissonette DJ, et al. The long-term outcome of microvascular decompression for trigeminal neuralgia. N Engl J Med. 1996;334(17):1077-1083. https://doi.org/10.1056/NEJM199604253341701
  104. Chu DT, Hautecoeur P, Santoro JD. Jacques Jean Lhermitte and Lhermitte’s sign. Mult Scler. 2020;26(4):501-504.  https://doi.org/10.1177/1352458518820628
  105. Al-Araji AH, Oger J. Reappraisal of Lhermitte’s sign in multiple sclerosis. Mult Scler. 2005;11(4):398-402.  https://doi.org/10.1191/1352458505ms1177oa
  106. Kanchandani R, Howe JG. Lhermitte’s sign in multiple sclerosis: a clinical survey and review of the literature. J Neurol Neurosurg Psychiatry. 1982;45(4):308-312.  https://doi.org/10.1136/jnnp.45.4.308
  107. Etemadifar M, Mehrbod N, Dehghani L, et al. Prevalence of Lhermitte’s sign in multiple sclerosis versus neuromyelitis optica. Iran J Neurol. 2014;13(1):50-51. 
  108. Teoli D, Rocha Cabrero F, Ghassemzadeh S. Lhermitte Sign. 2020 Oct 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. PMID: 29630289.
  109. Gutrecht JA, Zamani AA, Slagado ED. Anatomic-radiologic basis of Lhermitte’s sign in multiple sclerosis. Arch Neurol. 1993;50(8):849-851.  https://doi.org/10.1001/archneur.1993.00540080056014
  110. Khan N, Smith MT. Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models. Inflammopharmacology. 2014;22(1):1-22.  https://doi.org/10.1007/s10787-013-0195-3
  111. Sá MJ. Physiopathology of symptoms and signs in multiple sclerosis. Arq Neuropsiquiatr. 2012;70(9):733-740.  https://doi.org/10.1590/s0004-282x2012000900016
  112. Saguil A, Kane S, Farnell E. Multiple sclerosis: a primary care perspective. Am Fam Physician. 2014;90(9):644-652. 
  113. Beckmann Y, Özakbaş S, Bülbül NG, et al. Reassessment of Lhermitte’s sign in multiple sclerosis. Acta Neurol Belg. 2015;115(4):605-608.  https://doi.org/10.1007/s13760-015-0466-4
  114. Franceschini PR, Worm PV. Ependymal cyst presenting with Lhermitte sign. Global Spine J. 2014;4(2):101-104.  https://doi.org/10.1055/s-0033-1357301
  115. Archibald SJ, Mateer CA, Kerns KA. Utilization behavior: clinical manifestations and neurological mechanisms. Neuropsychol Rev. 2001;11(3):117-130.  https://doi.org/10.1023/a:1016673807158
  116. Porta-Etessam J, Martínez-Salio A, Berbel A, et al. Fenómeno de Lhermitte en tres pacientes oncológicos Rev Neurol. 2000;30(7):649-651. 
  117. Reeves RR, Pinkofsky HB. Lhermitte’s sign in paroxetine withdrawal. J Clin Psychopharmacol. 1996;16(5):411-412.  https://doi.org/10.1097/00004714-199610000-00013
  118. Ekbom K. Carbamazepine: A Symptomatic Treatment of the Paresthesiae Associated with Lhermitte’s Sign. Ann Indian Acad Neurol. 2017;20(2):166.  https://doi.org/10.4103/aian.AIAN_21_17
  119. Truini A, Galeotti F, Cruccu G. Treating pain in multiple sclerosis. Expert Opin Pharmacother. 2011;12(15):2355-2368. https://doi.org/10.1517/14656566.2011.607162
  120. Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci. 1999;162(2):162-168.  https://doi.org/10.1016/s0022-510x(98)00322-0
  121. Sandyk R, Dann LC. Resolution of Lhermitte’s sign in multiple sclerosis by treatment with weak electromagnetic fields. Int J Neurosci. 1995;81(3-4):215-224.  https://doi.org/10.3109/00207459509004888
  122. Yakovlev AE, Parmentier AM. Resolution of Lhermitte’s sign with spinal cord stimulation. Pain Med. 2014;15(1):167-169.  https://doi.org/10.1111/pme.12215

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.